In vitro and in vivo evaluation demonstrates enhanced delivery and melanogenesis inhibition by arbutin-chitosan nanoparticle gel, suggesting an effective topical treatment for hyperpigmentation.
Objective(s): In the present study, a cross-linking gelation method combined with ultrasound was employed to create arbutin (ARB)-incorporated chitosan (CHT) nanoparticles (NPs). This approach aims to enhance cutaneous absorption and improve anti-melanogenesis effects.Material and Methods: Environmentally-friendly preparation of NP, monitoring NP features, checking structure, animal safety application, cellular viability, and inhibitory assessment on melanin creation were performed.Results: The results showed that increasing the volume ratio of chitosan (CHT) to tripolyphosphate (TPP) from 10:1.25 to 10:5 resulted in a reduction of particle size from 1097.133 ± 28.655 nm to 215.666 ± 5.976 nm. Moreover, this CHT/TPP volume ratio increase from 10:1.25 to 10:5 enhanced the encapsulation efficiency, from 55.084 ± 4.283% to 97.151 ± 0.066%. Assessment of cutaneous absorption revealed that the ARB-CHT-NP gel delivered significantly more arbutin (ARB) to both the cutaneous layers (46.168 ± 3.313% or 810.094 ± 58.147 μg/cm²) and the receiver compartment (34.155 ± 2.699% or 599.314 ± 47.371 μg/cm²) compared to the ARB plain gel. In vitro cytotoxicity testing demonstrated that, in the presence of the optimal formulation, a higher percentage of cell survival was observed in the HFF cell line compared to kojic acid and ARB. Additionally, the ARB-CHT-NP gel exhibited greater cytotoxicity in the B16F10 cell line compared to the other groups. A cutaneous itching assay on Wistar rats showed no signs of sensitivity to the ARB-CHT-NP gel. Furthermore, ARB-CHT-NP inhibited melanogenesis more effectively than kojic acid and ARB. L-dopa auto-oxidation was also significantly inhibited by ARB-CHT-NP (56.971 ± 1.265%) compared to kojic acid (46.141 ± 1.169%) and ARB (41.308 ± 1.967%).Conclusion: Based on the results, the ARB-CHT-NP could serve as a prospective nanocarrier for ARB cutaneous application. Therefore, it is recommended that its use for treating melasma be considered.
No takes yet. Share an insight, caveat, or question.
Omidi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: